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Abstract
The ability to diagnose pancreatic carcinoma has been rapidly improving with the recent advances in diagnostic techniques
such as contrast-enhanced Doppler ultrasound (US), helical computed tomography (CT), enhanced magnetic resonance
imaging (MRI), and endoscopic US (EUS). Each technique has advantages and limitations, making the selection of the
proper diagnostic technique, in terms of purpose and characteristics, especially important. Abdominal US is the modality
often used first to identify a cause of abdominal pain or jaundice, while the accuracy of conventional US for diagnosing
pancreatic tumors is only 5070%. CT is the most widely used imaging examination for the detection and staging of
pancreatic carcinoma. Pancreatic adenocarcinoma is generally depicted as a hypoattenuating area on contrast-enhanced
CT. The reported sensitivity of helical CT in revealing pancreatic carcinoma is high, ranging between 89% and 97%. Multi-
detector-row (MD) CT may offer an improvement in the early detection and accurate staging of pancreatic carcinoma. It
should be taken into consideration that some pancreatic adenocarcinomas are depicted as isoattenuating and that
pancreatitis accompanied by pancreatic adenocarcinoma might occasionally result in the overestimation of staging. T1-
weighted spin-echo images with fat suppression and dynamic gradient-echo MR images enhanced with gadolinium have
been reported to be superior to helical CT for detecting small lesions. However, chronic pancreatitis and pancreatic
carcinoma are not distinguished on the basis of degree and time of enhancement on dynamic gadolinium-enhanced MRI.
EUS is superior to spiral CT and MRI in the detection of small tumors, and can also localize lymph node metastases or
vascular tumor infiltration with high sensitivity. EUS-guided fine-needle aspiration biopsy is a safe and highly accurate
method for tissue diagnosis of patients with suspected pancreatic carcinoma. 18F-fluorodeoxyglucose (FDG) positron
emission tomography (PET) has been suggested as a promising modality for noninvasive differentiation between benign and
malignant lesions. Previous studies reported the sensitivity and specificity of FDG-PET for detecting malignant pancreatic
tumors as being 71100% and 6490%, respectively. FDG-PET does not replace, but is complementary to morphologic
imaging, and therefore, in doubtful cases, the method must be combined with other imaging modalities.
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Introduction
Pancreatic ductal adenocarcinoma has one of the
most unfavorable prognoses. The only curative treat-
ment is surgery, but the reported 5-year survival rates
are only from 2 to 10% [1,2]. To raise these survival
rates, early and accurate diagnosis is required. There
are three steps in the diagnosis of pancreatic carci-
noma before deciding on the treatment approach. The
first step is to detect the tumor. One of the reasons for
the low survival rates is the difficulty in making an
early diagnosis. The higher the sensitivity for detect-
ing pancreatic tumors, the greater the number of
patients with early pancreatic cancer can be expected
to be. The next step is to differentiate pancreatic
adenocarcinoma from other pancreatic diseases
such as chronic pancreatitis, benign or malignant islet
cell tumor, and intraductal papillary mucinous neo-
plasm. Finally, imaging should be able to permit
staging of the tumor. In the case of pancreatic cancer,
any infiltration of vessels and lymph nodes as well as
possible distant metastases takes on special impor-
tance due to the impact on the assessment of
resectability of the tumor or the decision to initiate
chemotherapy.
In recent years, diagnostic imaging techniques
such as multi-detector-row computed tomography
(MDCT), magnetic resonance imaging (MRI) and
endoscopic ultrasound (EUS) have been developed,
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elevating the ability to diagnose pancreatic carcinoma,
although there are still inherent limitations. It is
important to select the proper diagnostic technique
in line with the purpose and characteristics of those
procedures. This article reviews recent progress in the
diagnosis of pancreatic adenocarcinoma.
Ultrasonography (US)
Abdominal US is often the first approach used in
attempting to identify the cause of abdominal pain or
jaundice, as it is a noninvasive and cost-effective
method. Low echoic mass, dilatation of the pancreatic
duct, and dilatation of the common bile duct on
conventional US are signs of the presence of pancrea-
tic tumor [3,4]. By conventional US, most pancreatic
tumors  including pancreatic adenocarcinoma,
chronic pancreatitis, and endocrine cell tumors 
are revealed as a hypoechoic area in the pancreas. In
other words, there are no characteristic signs for the
different pancreatic lesions. The accuracy of conven-
tional US for diagnosing pancreatic tumors is only
5070% [4].
Contrast-enhanced Doppler US has been proposed
as a valuable technique for the diagnosis of pancreatic
tumors. Characteristic signs of pancreatic tumors
have been reported with the use of contrast-enhanced
Doppler US [4]. Pancreatic adenocarcinoma was
found to be hypovascularized, whereas endocrine
cell tumor is mostly hypervascularized and pancrea-
titis-associated mass is mostly isovascularized. Kitano
et al. [5] assessed the usefulness of coded phase
inversion harmonic imaging, a newly available sono-
graphic technique based on a combination of phase
inversion harmonics and coded technology, for the
depiction and differential diagnosis of pancreatic
tumors. They reported that the sensitivity and speci-
ficity of contrast-enhanced coded phase inversion
harmonic US for pancreatic ductal carcinoma were
90% and 95%, respectively.
The presence of obscuring overlying bowel gas and
the variable skill of the operator limit the sensitivity of
US for identification and staging of pancreatic lesions.
US may be an initial screening examination, generally
followed by CT and MRI for more accurate diagnosis
of pancreatic lesions.
CT
CT is the most widely used imaging examination for
the detection and staging of pancreatic carcinoma.
Pancreatic carcinoma is characterized by abundant
fibrous stroma and hypovascularity (Figure 1), which
accounts for the poor enhancement of the tumor
compared with that of the surrounding pancreatic
parenchyma, as seen in the early phase of dynamic CT
and gradual enhancement at delayed CT. Lu et al. [6]
reported that the mean tumorpancreas contrast
during the pancreatic phase (4070 s after infusion
of intravenous contrast material at 3 ml/s) was sig-
nificantly greater than the hepatic phases (70100 s
after infusion) by implementing two-phase helical CT
with scanning during both phases. Their technique
has improved the detectability of pancreatic adeno-
carcinoma, which tends to be enhanced less than the
surrounding parenchyma on pancreatic phase images.
The reported sensitivity of helical CT in revealing
pancreatic carcinoma is high, ranging between 89%
and 97% [7]. Pancreatic adenocarcinoma is generally
depicted as a hypoattenuating area on contrast-
enhanced CT, although some such tumors appear as
isoattenuating areas. Prokesch et al. [8] reported that
in 6 (11%) of 53 patients with pancreatic adenocarci-
nomas, the tumors were seen as isoattenuating. They
also emphasized that indirect signs such as mass
effect, atrophic distal parenchyma, and interrupted
duct sign were important indicators of the presence of
tumors with no visible tumorpancreas contrast. It
should also be kept in mind that pancreatitis accom-
panied by pancreatic adenocarcinoma might occa-
sionally be the cause of staging overestimation.
Thickening of the superior mesenteric artery is seen
in both cancer invasion and infiltration of fat in acute
or chronic pancreatitis [9] (Figure 2).
Several reports concluded that local extension of
pancreatic cancer and invasion of adjacent vascular
structures could be well depicted with helical CT,
with the main limitations of this technique for
preoperative staging being a difficulty in revealing
unsuspected liver metastases and a low rate of
revealing lymph node metastasis [7,10,11].
The recent development of MDCT allows the use
of extremely thin collimation for the acquisition of
high-resolution scans during multiple phases of con-
trast enhancement. Thus, greater parenchymal, arter-
ial, and portal venous enhancement may be achieved
when imaging the pancreas with MDCT, and this
technique may offer an improvement in the early
detection and accurate staging of pancreatic carci-
noma [1214]. MDCT technology has allowed the
Figure 1. A 76-year-old man with pancreatic head carcinoma. CT
revealed hypovascular tumor (arrow) in the head of the pancreas.
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acquisition of excellent three-dimensional images.
Three-dimensional reconstruction techniques such
as curved planar reformation, volume rendering,
and maximum intensity projection can provide an
excellent and quickly comprehensible overview of
pertinent anatomy and structures (Figure 3) that are
likely to be of great use to referring physicians and
surgeons [1214].
Endoscopic retrograde cholangiopancreato-
graphy (ERCP)
Pancreatic carcinoma is detectable only if it impinges
on the pancreatic duct, meaning that small early
cancer and that situated in the uncinate process can
be missed by this investigation. ERCP has the
advantage of providing the opportunity both to
sample for cytology or histology and to apply
important therapy via biliary stenting for obstructive
jaundice. The indication of ERCP for preoperative
diagnosis of pancreatic cancer has been declining
owing to advances of MR cholangiopancreatography
(MRCP  see below). Diagnostic ERCP may not be
indicated in patients with clinically evident pancreatic
cancer, but it may be valuable if a tumor is suspected
despite negative results on US and CT, or may be
used as an additional aid to differentiate between
chronic pancreatitis and cancer [11].
MRI
The ability of MRI to diagnose pancreatic carcinoma
has improved in concert with improvements in the
technology and its application. MRI offers several
benefits for imaging of the pancreas. One is the better
soft tissue contrast compared with CT before the
Figure 2. A 60-year-old man with pancreatic head carcinoma. (a) CT performed at a local hospital revealed a low-density area (thick arrow)
surrounding the superior mesenteric artery (thin arrow). The tumor was diagnosed as inoperable due to invasion to the superior mesenteric
artery. (b) CT performed 2 weeks later revealed that the low-density area surrounding the superior mesenteric artery had disappeared. A
low-density area surrounding the superior mesenteric artery was considered as corresponding to the acute inflammation of pancreatitis
accompanied by pancreatic carcinoma. Invasion to the superior mesenteric artery was ruled out. (c) CTat a more cranial slice revealed that
a tributary of the superior mesenteric artery (arrowhead) was involved in the tumor (thick arrow). (d) Three-dimensional reconstruction
CT revealed that the tributary of the superior mesenteric artery involved in the tumor was a replacement common hepatic artery
(arrowhead). Pancreatoduodenectomy combined with resection of the replaced common hepatic artery was performed. The common
hepatic artery was resected between its root and the root of the proper hepatic artery (dotted line) and reconstructed in an end-to-end
fashion.
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administration of contrast material. Another is the
possibility to examine the pancreatobiliary system
noninvasively. MRCP obtained with long echo times
on T2-weighted MR images can demonstrate the
biliary and pancreatic ductal systems.
The typical appearance of pancreatic carcinoma on
MRI is hypointense on T1-weighted images and
hyperintense or isointense on T2-weighted images.
The tumor shows diminished enhancement in the
early phase of dynamic MR imaging and gradual
enhancement in the late phase. T1-weighted spin-
echo images with fat suppression and dynamic gra-
dient-echo MR images enhanced with gadolinium
have been reported to be superior to helical CT for
detecting small lesions [15,16]. Mangafodipir triso-
dium, a contrast agent originally designed for MRI of
the liver, also shows uptake in the pancreatic par-
enchyma but not in pancreatic tumors. In a study
comparing gadolinium- and mangafodipir trisodium-
enhanced MR images of patients with suspected
pancreatic tumor, gradient-recalled echo images
enhanced with mangafodipir trisodium were signifi-
cantly better at delineating pancreatic tumors than
those enhanced with gadolinium chelates [17].
Chronic pancreatitis remains difficult to differenti-
ate from pancreatic carcinoma on the basis of imaging
criteria since both demonstrate low signal intensity on
T1-weighted images and are associated with pancrea-
tic and/or biliary ductal obstruction. Jenkins et al. [18]
found no statistically significant difference in T1 and
T2 between chronic pancreatitis and pancreatic
carcinoma. Johnson and Outwater [19] assessed the
ability of dynamic gadolinium-enhanced MRI for
differentiating chronic pancreatitis and pancreatic
carcinoma, concluding that they could not be
distinguished on the basis of degree and time of
enhancement. Ichikawa et al. [20] reported that the
duct-penetrating sign on MRCP images was more
helpful for distinguishing chronic pancreatitis from
pancreatic carcinoma than were the enhancement
patterns on CT and MR images.
Both gadolinium- and mangafodipir trisodium-
enhanced MR images are useful for evaluating local
tumor extension and vascular involvement of pan-
creatic carcinoma. Enhanced MRI has equal or better
accuracy than helical CT in determination of local
tumor extent and vascular involvement except for
duodenal invasion and portal venous system involve-
ment [2022].
EUS
The typical features of pancreatic carcinoma seen by
EUS include an inhomogeneous solid mass with
irregular borders that appears hypoechoic compared
with normal pancreatic parenchyma. EUS is highly
sensitive in the detection of small tumors and invasion
of major vascular structures. Thus, EUS is superior to
spiral CT, MRI and PET in the detection of small
tumors [23,24], and it can also locate lymph node
metastases and vascular tumor infiltration with high
sensitivity [25]. The major drawbacks of the techni-
que are operator dependence and limited field of
visualization for detecting metastatic spread to the
liver and peritoneum [23]. EUS-guided fine needle
aspiration biopsy is a safe and highly accurate method
for tissue diagnosis of patients with suspected pan-
creatic carcinoma [26,27]. While a positive diagnosis
can be relied upon for a management decision on the
basis of high specificity and a positive predictive value,
a negative result cannot be completely reassuring.
Considerable limitations of the EUS-guided fine
needle aspiration biopsy in the diagnosis of pancreatic
lesions are a relatively high number of inadequate
specimens and false negative results [28].
Figure 3. A 51-year-old woman with pancreatic head carcinoma.
(a) Conventional CT performed at a local hospital revealed a low-
density area in the head of the pancreas and the boundary to the
portal vein was unclear (arrow). At that hospital, the tumor was
diagnosed as inoperable due to portal vein invasion. (b) MPR
(multi-planar reconstruction) images obtained by MDCT revealed
that the portal vein was intact. Pancreatoduodenectomy combined
with resection of the portal vein was performed. Histopathological
examination showed no invasion to the portal vein (arrow).
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Positron emission tomography (PET)
PET using the radiolabeled glucose analog 18F-
fluorodeoxyglucose (FDG) has been suggested as a
promising modality for noninvasive differentiation
between benign and malignant lesions. Increased
glucose utilization due to an increased number of
glucose transporter proteins and increased hexokinase
and phosphofructokinase activity is commonly found
in malignant tumors. Previous studies reported the
sensitivity and specificity of FDG-PET for detecting
malignant pancreatic tumors to be 71100% and 64
90%, respectively [29]. There are certain limitations
of FDG-PET imaging in the diagnosis of pancreatic
carcinoma. Chronic and acute pancreatitis can accu-
mulate FDG and result in false positive interpreta-
tions on PET imaging. It is well known that sensitivity
in hyperglycemic patients tends to be lower than in
euglycemic patients, as elevated serum glucose levels
result in decreased FDG uptake in tumors by up to
50% due to competitive inhibition. False negative
studies may also occur when the tumor is B/1 cm
[30]. This functional imaging does not replace, but is
complementary to morphologic imaging, and thus, in
doubtful cases, the method must be combined with
other imaging modalities.
There are other roles of FDG-PET in the manage-
ment of patients with pancreatic carcinoma. It is
useful for evaluating the prognostic value and for
monitoring treatment. Nakata et al. [31] reported that
patients with pancreatic adenocarcinoma with low
FDG uptake survived longer than patients with high
uptake. Maisey et al. [32] reported that the absence of
FDG uptake at 1 month following chemotherapy for
carcinoma of the pancreas is an indicator of improved
overall survival.
Conclusion
Recent advances in diagnostic techniques such as
contrast-enhanced Doppler US, helical CT, enhanced
MRI, and EUS have led to improvements in sensitiv-
ity for identifying pancreatic carcinoma. However,
differential diagnosis between pancreatic carcinoma
and chronic pancreatitis still remains difficult. EUS-
guided fine needle aspiration biopsy and FDG-PET
may help to differentiate those diseases. For staging
pancreatic carcinoma, CT, MRI, and EUS are all
valuable, but their limitations must also be taken into
account.
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